Prezent AI, the communications platform trusted by more than 150 life sciences companies—including 45 of the top 50 biopharma players—has launched Prezent Vivo, a new solution designed to power the entire life sciences communication ecosystem. The platform brings together purpose-built AI and domain experts into a single model, serving both biopharma companies and their agency partners.
Unlike most sectors, life sciences operates with virtually no margin for error. Communications frequently involve clinical data, regulatory frameworks, and patient-facing materials, where precision is critical. In this context, “good enough” output from general-purpose AI simply falls short. While these tools can accelerate early drafts, they often lack the scientific depth required, forcing teams into lengthy review cycles that erode much of the initial efficiency.
At the same time, traditional MedComms agencies remain essential. Their expertise ensures accuracy and compliance, but their workflows are inherently slower and resource-intensive. As demand for content grows across clinical, medical, and commercial functions, companies are left navigating a persistent tradeoff between speed and rigor.
Prezent Vivo is built to address that tension.
Drawing on years of experience working closely with life sciences organizations, Prezent has developed a platform that combines a purpose-built AI system with embedded human expertise. The result is what the company describes as a unified communication model—one that aims to deliver both speed and scientific precision at scale.
At the core of the platform is Astrid, an AI layer trained specifically for life sciences use cases. It is designed to understand regulatory language, clinical evidence structures, and brand requirements, enabling it to generate high-quality drafts quickly and reduce time spent on production-heavy tasks. From there, human experts—including medical writers, communication specialists, and presentation engineers—step in to validate, refine, and ensure that every output meets the standards expected in high-stakes environments.
This integration is central to Vivo’s value proposition. As Rajat Mishra argues, the future of life sciences communication lies not in choosing between AI and expertise, but in combining the two—allowing technology to deliver speed while human insight ensures substance.
The implications go beyond efficiency. By shifting routine production work to AI, organizations can free up expert talent to focus on higher-value activities such as scientific interpretation and strategic storytelling. According to the company, this model can also significantly reduce costs compared to traditional agencies, while enabling teams to scale output without increasing headcount.
Notably, Prezent is not positioning Vivo as a replacement for agencies. Instead, it frames the platform as an infrastructure layer—one that agencies can leverage to increase productivity and expand capacity. This reflects a broader shift in how AI is being adopted across the sector: not as a force that eliminates roles, but as one that reshapes them.
The launch of Prezent Vivo comes at a time when life sciences companies are rethinking how complex information is communicated. As data volumes grow and timelines accelerate, the ability to deliver clear, accurate, and timely content is becoming a strategic priority.
Whether Vivo becomes a new standard remains to be seen. What is clear, however, is that the conversation has moved beyond whether AI can be used in life sciences communication. The real question now is how to use it without compromising the very standards that define the industry.
